BioSpace News Archive

Amgen (NASDAQ:AMGN) today announced the Company has provided notice to Cytokinetics of termination of its collaboration and its intention to transition the development and commercialization rights for omecamtiv mecarbil and AMG 594.

GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced it has raised $16 million in a Series B financing led by MVM Partners with participation from existing investors MedTech Venture Partners and BlueStone Venture Partners.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced Nello Mainolfi, Co-Founder, President and CEO and Jared Gollob, Chief Medical Officer of Kymera Therapeutics, will present at the Piper Sandler 32nd Annual Healthcare Conference

Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in the following investor conferences: A virtual fireside chat at the Evercore ISI 3 rd Annual HealthCONx Conference on Wednesday, Dec. 2, 2020, at 2:15 p.m. ET; and Meetings at the Piper Sandler 32 nd Annual Virtual Healthcare Conference o

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that members of the Avadel management team will present at both the 32nd Annual Piper Sandler Virtual Healthcare Conference and the 3rd Annual Evercore ISI HealthCONx Conference that are being held in

Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the filing of an Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA) for ON 123300, the Company’s proprietary, differentiated, first-in-class multi-kinase inhibitor.

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate immunological pathways across a spectrum of diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted the supplemental Biologics License Application (sBLA) for rilonacept in recurrent pericarditis

Chinese leading biopharmaceutical company, 3SBio Inc.(01530.HK, the “Company” ), announced today that Selecta Biosciences, Inc. (Nasdaq: SELB), the Company’s partner, has commenced the phase III clinical program of a combination therapy involving SEL-212 for the treatment of chronic refractory gout on behalf of Sobi TM , and has

Beckman Coulter, a clinical diagnostics leader, today launched its Access SARS-CoV-2 IgG II assay that measures a patient’s relative level of antibodies in response to a previous SARS-CoV-2 infection

- Eiger and The Progeria Research Foundation will share proceeds 50/50 - Non-dilutive capital further strengthens Eiger’s balance sheet